Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L‐asparaginase induction therapy in pediatric acute lymphoblastic leukemia
Open Access
- 25 September 2019
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (1) , e28016
Abstract
Background: L‐asparaginase (L‐Asp)‐associated thromboembolisms are serious complications in pediatrics patients with acute lymphoblastic leukemia (ALL), especially at ≥10.0 years old, but the pathogenesis remains to be clarified.Procedure: We conducted a multicenter, prospective study of 72 patients with ALL aged 1.0 to 15.2 years treated with either a Berlin‐Frankfurt‐Münster (BFM) 95‐ALL oriented regimen or Japan Association of Childhood Leukemia Study ALL‐02 protocol. We divided patients into each treatment protocol and investigated the dynamic changes in coagulation and fibrinolysis using simultaneous thrombin and plasmin generation assay. Patients’ plasma samples were collected at the prephase (T0), intermittent phase (T1), and postphase of L‐Asp therapy (T2), and postinduction phase (T3). Measurements of endogenous thrombin potential (T‐EP) and plasmin peak height (P‐Peak) were compared to normal plasma.Results: None of the cases developed thromboembolisms. Median ratios of T‐EP and P‐Peak for the controls in the JACLS group were 1.06 and 0.87 (T0), 1.04 and 0.71 (T1), 1.02 and 0.69 (T2), and 1.20 and 0.92 (T3), respectively, while those in the BFM group were 1.06 and 1.00 (T0), 1.04 and 0.64 (T1), 1.16 and 0.58 (T2), and 1.16 and 0.85 (T3), respectively. In particular, P‐Peak ratios were depressed at T1 and T2 compared to T0 in the BFM group (P < .01). Moreover, P‐Peak ratios in patients ≥10.0 years old were lower at T1 in the BFM group (P = .02).Conclusions: The results demonstrated that hemostatic dynamics appeared to shift to a hypercoagulable state with marked hypofibrinolysis associated with L‐Asp therapy, especially in patients ≥10.0 years old following the BFM regimen.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (18K07885)
This publication has 30 references indexed in Scilit:
- Fibrinolytic abnormality associated with progression of pediatric solid tumorPediatrics International, 2018
- First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillinInternational Journal of Hematology, 2017
- Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantationInternational Journal of Hematology, 2017
- Haemostatic alterations induced by treatment with asparaginases and clinical consequencesThrombosis and Haemostasis, 2015
- Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysisThrombosis and Haemostasis, 2013
- Asparaginase‐related venous thrombosis in UKALL 2003‐ re‐exposure to asparaginase is feasible and safeBritish Journal of Haematology, 2010
- Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemiaBritish Journal of Haematology, 2010
- Double Hazard of Thrombophilia and Bleeding in LeukemiaHematology-American Society Hematology Education Program, 2007
- Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patientsBlood, 2006
- Thrombosis in children with acute lymphoblastic leukemiaThrombosis Research, 2003